January 23, 2024
Nippon Shinyaku said on January 22 that European regulators have granted orphan drug designation for NS-229, which is being developed for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). The designation, awarded by the European Commission, provides the drug with...read more